IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3814
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$10M
Brian M. Strem
Kiora Pharmaceuticals, Inc. develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$KPRX KIORA PHARMACEUTICALS INC | 38 | 32 | 20 | 20 | 196.0x | - | -34.5% | -25.9% | - | - | - | -100.0% | 0.0% | 0.0x | $10M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
KIORA PHARMACEUTICALS INC (KPRX) receives a "Avoid" rating with a composite score of 37.7/100. It ranks #3814 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for KPRX.
View All RatingsROE proxy -34.5% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth -100%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate KIORA PHARMACEUTICALS INC (KPRX) as Avoid with a composite score of 37.7/100 at a current price of $2.03. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
KIORA PHARMACEUTICALS INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 37.7/100 places it at rank #3814 in our full universe.
No Moat
Low
Poor
Fair Value
Stable competitive position in a defensive sector.
Elevated P/E ratio of 196.0x leaves little room for execution misses.
Weak momentum suggests persistent institutional selling pressure.
Below-average quality raises earnings sustainability concerns.
KIORA PHARMACEUTICALS INC represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags KIORA PHARMACEUTICALS INC with an Avoid rating, assigning a composite score of 37.7/100 and 1 out of 5 stars. Ranked #3814 of 7,333 stocks, KPRX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
KPRX's quality score of 32/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -34.5% (sector avg: -1.9%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
KPRX registers a value score of just 20/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/E ratio of 196.00x, a P/B ratio of 0.32x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
KIORA PHARMACEUTICALS INC's investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -100.0% vs. a sector average of 6.7% and a return on assets of -25.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
KIORA PHARMACEUTICALS INC is experiencing notably weak momentum with a score of just 20/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -100.0% year-over-year, while a beta of 0.49 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 60/100, KPRX exhibits average financial resilience. Key stability metrics include a beta of 0.49 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
KPRX's short interest factor score of 88/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include micro-cap liquidity risk. As a micro-cap company with a market capitalization of $10M, KIORA PHARMACEUTICALS INC benefits from the generally lower volatility and deeper liquidity associated with its size class.
KIORA PHARMACEUTICALS INC is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3814 of 7,333 overall (48th percentile). Key comparisons include ROE of -34.5% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While KPRX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (20) would have the largest impact on the composite score.
ROE 1716% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 100% BELOW SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET.A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section. A replay of the webcast will be available for approximately 90 days.About Kiora...
Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advisor, Dr. Sakamoto, currently the Chair of Ophthalmology at Kagoshima University, will contribute clinical and scientific insights to Kiora as it develops new therapeutics to address retinal diseases with high unmet needs. "As we deepen our...
HC Wainwright & Co. has decided to maintain its Buy rating of Kiora Pharmaceuticals (NASDAQ:KPRX) and raise its price target from $3.50 to $2.00. Shares of Kiora Pharmaceuticals are trading down 0.84% over the last 24 hours, at $0.66 per share. A move to $2.00 would account for a 202.57% increase from the current share price. About Kiora Pharmaceuticals Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in ...Full story available on Benzinga.com
Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company reported mixed fourth-quarter financial results. Skechers said fourth-quarter revenue increased 4.4% year-over-year to $1.96 billion, which missed the consensus estimate of $2.03 billion, according to Benzinga Pro. The company reported quarterly earnings of 56 cents per share, which beat analyst estimates of 54 cents per share. Skechers shares fell 6.9% to $59.21 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares jumped 77.6% to $4.28. Intelligent Bio Solutions said it sees preliminary second-quarter revenue of $0.76 million. Minim, Inc. (NASDAQ: MINM) shares rose 34.4% to $6.76 after gaining more than 22% on Thursday. Remark Holdings, Inc. (NASDAQ: MARK) shares climbed 33% to $0.6802. Kopin Corporation (NASDAQ: KOPN) jumped 30% to $2.4050. BioRestorative Therapies, Inc. (NASDAQ: BRTX) rose 26.3% to $2.73. Mountain Crest Acquisition Corp. IV (NASDAQ: MCAF) gained 23% to $14.65. Tyra Biosciences, Inc. (NASDAQ: TYRA) gained 21.8% to $15.84. Tyra Biosciences announced a $200 million private placement financing. Meta Platforms, Inc. (NASDAQ: META) rose 18.9% to $469.34 as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share. CCSC Technology International Holdings Limited (NASDAQ: CCTG) gained 18.2% to $4.6099 after dipping around 82% on Thursday. Roma Green Finance Limited (NASDAQ: ROMA) gained 15.8% to $0.8697 after gaining around 5% on Thursday. Deckers Outdoor Corporation (NYSE: DECK) surged 14% to $879.03 after reporting better-than-expected third-quarter financial results. Trugolf, Inc. (NASDAQ: TRUG) shares jumped 14% to ...
Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the company reported upbeat fourth-quarter financial results and initiated a quarterly dividend of 50 cents per share. The company also announced a $50 billion increase to its share repurchase authorization. Meta shares climbed 16.5% to $460.02 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers CCSC Technology International Holdings Limited (NASDAQ: CCTG) gained 55.1% to $6.05 in pre-market trading after dipping around 82% on Thursday. Trugolf, Inc. (NASDAQ: TRUG) shares jumped 33.1% to $1.77 in pre-market trading after dipping 55% on Thursday. Roma Green Finance Limited (NASDAQ: ROMA) gained 25.2% to $0.94 in pre-market trading after gaining around 5% on Thursday. Jiuzi Holdings, Inc. (NASDAQ: JZXN) shares gained 20% to $0.84 in pre-market trading. C3is Inc. (NASDAQ: CISS) shares rose 18.8% to $0.1625 in pre-market trading. S.H.N. Financial recently reported a 9.1% stake in the company. Minim, Inc. (NASDAQ: MINM) shares rose 18.7% to $5.97 in pre-market trading after gaining more than 22% on ...